Moteur de recherche d’entreprises européennes
Financement de l’UE (3 583 870 €) : Exploiter la comPLEXité de la maladie MELanoma pour répondre aux besoins de formation de la recherche européenne dans les domaines de la biologie translationnelle … Hor01/12/2014 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Exploiter la comPLEXité de la maladie MELanoma pour répondre aux besoins de formation de la recherche européenne dans les domaines de la biologie translationnelle des systèmes cancéreux et de la médecine des systèmes cancéreux
Novel treatment options and associated personalised, patient-tailored therapies need to be explored and developed for highly heterogeneous and chemotherapy resistant cancers, such as malignant melanoma. This can only be achieved by industry-academia collaborations in newly emerging, innovative research disciplines such as translational cancer systems biology and systems medicine. These disciplines and the associated European training needs provide the foundation for the MEL-PLEX ETN. MEL-PLEX aims to understand the network-level and multi-scale regulation of disease-relevant signalling in melanoma through a combination of quantitative biomedical and computational research approaches that go significantly beyond the current state-of-the-art. Coordinated by the RCSI Centre for Systems Medicine, MEL-PLEX will train 15 early stage researchers through a highly interdisciplinary and intersectoral research training programme. MEL-PLEX comprises 11 beneficiaries and 7 partner organisations from 11 countries, including European and international leaders in personalised melanoma therapy, melanoma systems biology and cancer systems medicine. MEL-PLEX aims to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) will exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) will provide superior and clinically relevant tools and biomarker signatures for personalising and optimising melanoma treatment. The MEL-PLEX ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans across biology, medicine and mathematics, that can navigate confidently between clinical, academic and private sector research environments, and that have developed an innovative and creative mindset to progress research findings towards applications.
| A. Plaisant Srl | ? |
| Katholieke Universiteit Leuven | 501 120 € |
| Kraeftens Bekaempelse | 290 082 € |
| Oncomark Ltd. | 265 675 € |
| OPTIMATA Ltd. | 260 301 € |
| Protavio Monoprosopi ΕΠΕ | 242 387 € |
| Royal College of Surgeons in Ireland | 184 496 € |
| RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | 55 381 € |
| TECHNISCHE UNIVERSITAET DRESDEN | 498 433 € |
| UNIVERSITAETSKLINIKUM AACHEN | 41 536 € |
| Universite Du Luxembourg | 501 120 € |
| University College Dublin, National University of Ireland, Dublin | 265 675 € |
| UNIVERSITY OF STUTTGART | 477 665 € |
https://cordis.europa.eu/project/id/642295
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : A. Plaisant Srl, Rome, Italie.
